

Yemen


Phase: Control.

I. EPIDEMIOLOGICAL PROFILE

| Population (UN Population Division) | 2010 | % |
|--|------------|----|
| High transmission (≥ 1 case per 1000 population) | 14 900 000 | 62 |
| Low transmission (0-1 cases per 1000 population) | 4 570 000 | 19 |
| Malaria-free (0 cases) | 4 570 000 | 19 |
| Total | 24 040 000 | |

Parasites and vectors

Major plasmodium species: *P. falciparum* (99%), *P. vivax*
 Major anopheles species: *An. arabiensis*, *culicifacies*, *sergentii*



II. INTERVENTION POLICIES AND STRATEGIES

| Intervention | WHO-recommended policies/strategies | Yes/No | Year adopted |
|-----------------|---|--------|--------------|
| ITN | ITNs/LLINs: distributed free of charge | Yes | 2002 |
| | ITNs/LLINs: distributed to all age groups | Yes | 2009 |
| IRS | IRS is recommended | Yes | 2001 |
| | DDT is used for IRS | No | - |
| IPT | IPT used to prevent malaria during pregnancy | NA | - |
| | Patients of all ages should receive diagnostic test | Yes | 2001 |
| Case management | RDTs used at community level | Yes | 2009 |
| | ACT is free for all ages in public sector | Yes | 2009 |
| | Pre-referral treatment with recommended medicines | Yes | 2009 |
| | Oral artemisinin-based monotherapies are not registered | Yes | 2009 |



| Antimalarial policy | Medicine | Year adopted |
|--|------------|--------------|
| First-line treatment of unconfirmed malaria | AS+SP | 2009 |
| First-line treatment of <i>P. falciparum</i> | AS+SP | 2009 |
| Treatment failure of <i>P. falciparum</i> | AL | 2009 |
| Treatment of severe malaria | AM;QN | 2009 |
| Treatment of <i>P. vivax</i> | CQ+PQ(14d) | - |

Therapeutic efficacy tests (therapeutic or parasitological failure, %)

| Medicine | Year | No. of Studies | Min | Median | Max | Follow-up |
|----------|-----------|----------------|-----|--------|-----|-----------|
| AS+SP | 2007-2007 | 2 | 0 | 0.75 | 1.5 | 28 days |



III. FINANCING – Government and external financing

Expenditure by intervention in 2010



IV. COVERAGE – Coverage of ITN and IRS

Cases tested and ACT delivered: Programme data (public sector)



V. IMPACT – Malaria test positivity rate and ABER

Confirmed cases, admissions and deaths (per 100 000)

